This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Berger & Montague, P.C. Files Class Action Suit Against ViroPharma Incorporated For Alleged Misrepresentations About Generic Competition

For more information about this case, please contact

Sherrie R. Savett, Esq. Carole A. Broderick, Esq. Douglas R. Risen, Esq.BERGER & MONTAGUE, P.C.1622 Locust Street Philadelphia, PA 19103888-891-2289 info@bm.net www.bergermontague.com

Berger & Montague, P.C. has extensive experience in securities litigation involving securities law violations regarding drugs and matters concerning Food and Drug Administration law and regulations, including a successful action for violation of the federal securities laws against ViroPharma concerning a drug under development that purportedly reduced the duration of the common cold, which was abandoned by the Company.  Berger & Montague has also successfully litigated actions for violations of the securities laws against Nuvelo, Inc., Hemispherix Biopharma, CryoLife, Inc., Cephalon, Inc., Genentech, Inc., Sepracor, Inc., U.S. Bioscience, Synergen, Inc., Cryomedical Sciences, MediImmune, Inc., and Andrx Corp.

The firm was founded in 1970, is a pioneer in class action litigation.  The firm's 70 attorneys concentrate their practice in complex litigation, including securities fraud, whistleblower and false claims actions and have recovered several billion dollars for consumers and investors.

SOURCE Berger & Montague, P.C.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs